Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques

Molecular Imaging and Biology

Volumn 18, Issue 1, 2016, Pages 99-108

  Rinne, Petteri ^a   Hellberg, Sanna ^a   Kiugel, Max ^a   Virta, Jenni ^a   Li, Xiang Guo ^a   Käkelä, Meeri ^a   Helariutta, Kerttuli ^b   Luoto, Pauliina ^a   Liljenbäck, Heidi ^a,c   Hakovirta, Harri ^c   Gardberg, Maria ^a   Airaksinen, Anu J ^b   Knuuti, Juhani ^a   Saraste, Antti ^a   Roivainen, Anne ^a,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Atherosclerosis; Autoradiography; Biodistribution; Positron emission tomography; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N',N''' TETRAACETIC ACID NAL3 OCTREOTIDE GA 68; 5 DEOXY 5 FLUORORIBOSE NAL3 F 18; INTERLEUKIN 6; SOMATOSTATIN RECEPTOR 2; TRACER; UNCLASSIFIED DRUG; [1,4,7,10 TETRAAZACYCLODODECANE N,N',N',N''' TETRAACETIC ACID] DEXTRO PHENYLALANINE 1 OCTREOTIDE[3 TYROSINE] GA 68; 68GA-DOTANOC; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CYTOKINE; DOTATATE GALLIUM GA-68; LOW DENSITY LIPOPROTEIN RECEPTOR; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN B; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTORADIOGRAPHY; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PET SCANNER; PRIORITY JOURNAL; RADIOACTIVITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; BLOOD; C57BL MOUSE; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; STAINING; TISSUE DISTRIBUTION; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; APOLIPOPROTEINS B; AUTORADIOGRAPHY; BIOMARKERS; CYTOKINES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE, INBRED C57BL; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, LDL; RECEPTORS, SOMATOSTATIN; STAINING AND LABELING; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84955709951     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-015-0873-1     Document Type: Article

References (38)

1. Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410–1422
2. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519
3. Moore KJ, Sheedy FJ, Fisher EA (2013) Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 13:709–721
4. Swirski FK, Nahrendorf M (2013) Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339:161–166
5. Langer HF, Haubner R, Pichler BJ, Gawaz M (2008) Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 52:1–12
6. Tarkin JM, Joshi FR, Rudd JH (2014) PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 11:443–457
7. Rudd JH, Narula J, Strauss HW et al (2010) Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 55:2527–2535
8. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 45:1245–1250
9. Zhang Z, Machac J, Helft G et al (2006) Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med 6:3
10. Tahara N, Kai H, Ishibashi M et al (2006) Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48:1825–1831
11. Aziz K, Berger K, Claycombe K et al (2008) Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation 117:2061–2070
12. Paulmier B, Duet M, Khayat R et al (2008) Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events. J Nucl Cardiol 15:209–217
13. Buettner C, Rudd JH, Fayad ZA (2011) Determinants of FDG uptake in atherosclerosis. JACC Cardiovasc Imaging 4:1302–1304
14. 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med 51:193–197
15. 68Ga-DOTATATE autoradiographic, immunohistochemical and flow cytometric studies in apoE-deficient mice. Atherosclerosis 230:33–39
16. 18F-FDG, calcium burden and risk factors. EJNMMI Res 2:52
17. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32:724
18. Wild D, Schmitt JS, Ginj M et al (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338–1347
19. Kiviniemi A, Gardberg M, Autio A et al (2014) Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies. Acta Oncol 53:1125–1134
20. Heinonen SE, Leppänen P, Kholová I et al (2007) Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res 101:1058–1067
21. Silvola JM, Saraste A, Laitinen I et al (2011) Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging 4:1294–1301
22. Körner M, Waser B, Schonbrunn A et al (2012) Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 36:242–252
23. 68Ga-DOTANOC. Curr Radiopharm 6:72–77
24. 18F-labeling of Siglec-9 peptide for PET imaging of inflammation. Chem Commun (Camb) 49:3682–3684
25. 18F]fluororibose to glycosylate peptides for positron emission tomography. Nat Protoc 9:138–145
26. Rinne P, Silvola JM, Hellberg S et al (2014) Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice. Arterioscler Thromb Vasc Biol 34:1346–1354
27. 100/100 mice. EJNMMI Res 1:14
28. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157–198
29. Adams RL, Adams IP, Lindow SW et al (2005) Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 92:1493–1498
30. Armani C, Catalani E, Balbarini A et al (2007) Expression, pharmacology, and functional role of somatostatin receptor subtypes 1 and 2 in human macrophages. J Leukoc Biol 81:845–855
31. Schatka I, Wollenweber T, Haense C et al (2013) Peptide receptor-targeted radionuclide therapy alters inflammation in atherosclerotic plaques. J Am Coll Cardiol 62:2344–2345
32. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148:209–214
33. Schuett H, Oestreich R, Waetzig GH et al (2012) Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 32:281–290
34. Sheikine Y, Hansson GK (2004) Chemokines and atherosclerosis. Ann Med 36:98–118
35. Wallace AM, McMahon AD, Packard CJ et al (2001) Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104:3052–3056
36. Koh KK, Park SM, Quon MJ (2008) Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 117:3238–3249
37. Ducimetiere P, Eschwege E, Papoz L et al (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 19:205–210
38. Stout RW (1990) Insulin and atheroma. 20-yr perspective. Diabetes Care 13:631–654